Alnylam Pharmaceuticals, Inc.
COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS
Last updated:
Abstract:
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-.beta., and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-.beta., and SMAD2/3.
Status:
Application
Type:
Utility
Filling date:
6 May 2020
Issue date:
25 Mar 2021